.Attributes Medication, Posted online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Viewpoint asks for inclusion of patients with MASLD and measurement of liver end results in cardio-- renal-- metabolic trials, when data recommend mechanistically conceivable benefits and clinical security-- and also summarizes factors for trial concept and also regulative commendation.